(Q44124156)

English

Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

phase I clinical trial

0 references

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Joan Carles Galcerán

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Eduardo Díaz-Rubio

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Jose Luis Gonzalez Larriba

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

author name string

Joaquim Bellmunt

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Joan Albanell

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Luis Paz-Ares

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Miguel A Climent

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Juan J de la Cruz

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Vicente Guillem

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Hernan Cortés-Funes

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

José Baselga

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Spanish Oncology Genitourinary Group

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

language of work or name

0 references

publication date

1 August 2002

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

95

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

751-757

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.10762

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44124156&oldid=2106831939"